4.3 Review

Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality

期刊

EXPERT OPINION ON DRUG SAFETY
卷 7, 期 6, 页码 717-725

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1517/14740330802396984

关键词

adherence; cardiovascular; compliance; hypolipidemic; lipid-lowering; statins

向作者/读者索取更多资源

Background: Hypercholesterolemia is a major risk factor for cardiovascular disease. Objective: Treatment with hypolipidemic agents reduces the risk of vascular events both in primary and secondary prevention. Although compliance with lipid-lowering therapy is an important determinant of cardiovascular clinical outcomes, relatively little attention is being paid to this issue by physicians. Methods: We searched the literature using Pubmed up to 5 August 2008. Results: Compliance with lipid-lowering therapy is poor in clinical practice, especially in primary prevention. As many as 6 out of 10 patients may stop taking statins during the first 6 months following initiation of treatment. Poor compliance has been associated with worse clinical outcome and increased cardiovascular morbidity and mortality. importantly, statin withdrawal may be even worse compared with not taking statins at all. Several strategies may increase treatment adherence. Conclusions: Poor compliance with lipid-lowering treatment is an important health issue that has been associated with unfavorable cardiovascular outcome. increasing adherence rates should become a major concern for physicians.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据